Abstract:Purpose: A novel 18F-radiolabeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, was synthesized and evaluated for positron emission tomography (PET) imaging of Neuroendocrine tumors (NETs). [Al18F]NODA-MPAA-HTA was designed and synthesized by conjugating 18F nuclide with a modified KE108 peptide, a somatostatin analog with high affinity for all five subtypes of somatostatin receptors (SSTR 1-5), through coupling a bifunctional chelator (NODA) to target somatostatin receptor (SSTR) positive tumors. Methods: The amino group of KE108 peptide, a SSTRs-targeting pharmacophore, was conjugated with the carboxyl group of NODA by a condensation reaction to obtain the labeling precursor of [Al18F]NODA-MPAA-HTA, in which its precursor was obtained through Fmoc solid-phase methods. A novel methodology for Al18F labeling of chelating agent-biomolecule conjugates was used to synthesize [Al18F]NODA-MPAA-HTA. In vitro stabilities of [Al18F]NODA-MPAA-HTA were evaluated by incubating it in saline or bovine serum for 2 h. Ex vivo biodistribution and in vivo imaging of [Al18F]NODA-MPAA-HTA were further investigated to evaluate its SSTRs targeting ability and feasibility for the diagnosis of NETs using PET imaging. Results: [Al18F]NODA-MPAA-HTA was synthesized using a one-step 18F-AlF labeling procedure resulting in moderate radiochemical yield (60-80 %, non-decay corrected) and high radiochemical purity (>95 %). It exhibited good hydrophilicity and excellent stability in vitro, with a molar activity of 122 GBq/μmol. At 30 min and 60 min, the uptake of [Al18F] NODA-MPAA-HTA by HEK293-SSTR2 cells was 5.47 ± 0.97 %/105 cells and 12.11 ± 0.32 %/105 cells, respectively. The affinity of [Al18F]NODA-MPAA-HTA for SSTR2 was determined to be 8.77 ± 1.14 nM. In micro-PET imaging of HEK293-SSTR2 tumor-bearing mice, [Al18F]NODA-MPAA-HTA showed high tumor uptake of radioactivity and a high tumor-to-muscle ratio. Biodistribution results confirmed that radioactivity uptake in the tumor was significantly higher than that in the muscle by more than five-fold (P<0.001). Furthermore, the relatively low bone uptake of [Al18F]NODA-MPAA-HTA suggested that defluorination did not occur in vivo. These preliminary results provide experimental evidence for further study of Al18F-labeled somatostatin analogues as tumor probes for PET imaging of NETs. Conclusion: Fluorine-18 is widely used as a radionuclide for the production of radiopharmaceuticals for positron emission tomography (PET). Due to its short half-life (T1/2,109.8 min), its ease of production will facilitate the widespread dissemination of this radiopharmaceutical. A high-quality [Al18F]NODA-MPAA-HTA was synthesized with satisfactory yield. This radiopharmaceutical demonstrated higher tumor uptake and better tumor-to-muscle contrast, resulting to excellent image quality. These findings suggest that the novel 18F-labeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, is a promising tool for PET imaging of NETs.

Synthesis and Preclinical Evaluation of [18F]AlF‐NOTA‐Asp2‐PEG2‐Folate as a Novel Folate‐Receptor‐Targeted Tracer for PET Imaging

Preparation of Folate-Nota-al18f Targeting Folate Receptor and Its Micropet/ct Imaging

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Novel 99mTc radiolabeled folate complexes with PEG linkers for FR-positive tumor imaging: synthesis and biological evaluation

Synthesis and Biological Evaluation of (68) Ga-labeled Pteroyl-Lys Conjugates for Folate Receptor-Targeted Tumor Imaging.

18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of neuroendocrine tumors (NETs)

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Synthesis and Preliminary Evaluation of a 99mtc‐labeled Folate‐pamam Dendrimer for FR Imaging

18F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging

FAPI-04 PET/CT Using [18f]alf Labeling Strategy: Automatic Synthesis, Quality Control, and in Vivo Assessment in Patient

Synthesis and preclinical evaluation of novel 18 F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts

Synthesis and in vitro/in vivo evaluation of 99mTc-labeled folate conjugates for folate receptor imaging.

Synthesis and Preclinical Evaluation of Novel 18F-Labeled Fibroblast Activation Protein Tracers for Positron Emission Tomography Imaging of Cancer-Associated Fibroblasts.

[18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers

Development of a New FR-Targeting Agent 99Mtc-Hynfa with Improved Imaging Contrast and Comparison of Multimerization And/or PEGylation Strategies for Radio-Folate Modification.

Al18F Labeled Sulfonamide‐conjugated Positron Emission Tomography Tracer in Vivo Tumor‐targeted Imaging

Automatic Production and Preliminary PET Imaging of a New Imaging Agent [18F]alf-Fapt.

18F-labeled tracers targeting fibroblast activation protein

Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging

Biological evaluation of a novel stable peptide PET molecular probe [18F]AlF-NOTA-DVAP targeting to tumor cell surface GRP78

Synthesis and Biological Evaluation of 3-O-(2-18 F-fluoroethyl)-L-DOPA As A Potential PET Agent for Tumor Imaging